<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573920</url>
  </required_header>
  <id_info>
    <org_study_id>CHK01-02</org_study_id>
    <nct_id>NCT04573920</nct_id>
  </id_info>
  <brief_title>Atrasentan in Patients With Proteinuric Glomerular Diseases</brief_title>
  <acronym>AFFINITY</acronym>
  <official_title>A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinook Therapeutics U.S., Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinook Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety&#xD;
      of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive&#xD;
      loss of renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety&#xD;
      of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive&#xD;
      loss of renal function. Four initial cohorts will consist of patients with:&#xD;
&#xD;
        -  IgA nephropathy (IgAN) with urine protein:creatinine ratio (UPCR) of 0.5 to less than&#xD;
           1.0 g/g&#xD;
&#xD;
        -  Focal segmental glomerulosclerosis (FSGS)&#xD;
&#xD;
        -  Alport syndrome&#xD;
&#xD;
        -  Diabetic kidney disease (DKD) on top of background care of a RAS inhibitor and SGLT2&#xD;
           inhibitor&#xD;
&#xD;
      Additional cohorts may be added as data is available.&#xD;
&#xD;
      Approximately 20 patients will be enrolled in each cohort (approximately 80 patients total)&#xD;
      to receive 0.75 mg atrasentan for 52 weeks.&#xD;
&#xD;
      The primary objective of the study is to evaluate the effect of atrasentan on proteinuria&#xD;
      (for IgAN, FSGS, and Alport syndrome patients) or albuminuria (for DKD patients) levels.&#xD;
      Exploratory objectives include evaluating the change in kidney function over time as measured&#xD;
      by eGFR, safety and tolerability.&#xD;
&#xD;
      To facilitate study participation over this time period, where allowed by local regulations,&#xD;
      options for remote study visits using telemedicine and home health may be offered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proteinuria for IgAN, FSGS, and Alport syndrome patients</measure>
    <time_frame>Up to Week 12 or approximately 3 months</time_frame>
    <description>The change in urine protein:creatinine ratio (UPCR) from baseline to Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in albuminuria for DKD patients</measure>
    <time_frame>Up to Week 12 or approximately 3 months</time_frame>
    <description>The change in urine albumin:creatinine ratio (UACR) from baseline to Week 12</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>IgA Nephropathy</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Alport Syndrome</condition>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Diabetic Nephropathy Type 2</condition>
  <condition>Immunoglobulin A Nephropathy</condition>
  <arm_group>
    <arm_group_label>Atrasentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral administration of 0.75 mg atrasentan for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrasentan</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Atrasentan</arm_group_label>
    <other_name>CHK-01</other_name>
    <other_name>Atrasentan Hydrochloride</other_name>
    <other_name>ABT-627</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older for patients in the IgAN, FSGS, and Alport syndrome cohort&#xD;
&#xD;
          -  Age 18-70 years for patients in the DKD cohort&#xD;
&#xD;
          -  Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has&#xD;
             been stable for at least 12 weeks.&#xD;
&#xD;
          -  For patients enrolling in IgAN Cohort:&#xD;
&#xD;
               1. Biopsy-proven IgA nephropathy&#xD;
&#xD;
               2. UPCR between 0.5 to less than 1.0 g/g&#xD;
&#xD;
               3. Screening eGFR ≥ 30 mL/min/1.73 m2&#xD;
&#xD;
          -  For patients enrolling in FSGS Cohort:&#xD;
&#xD;
               1. Biopsy-proven FSGS or documented genetic mutation in a podocyte protein&#xD;
                  associated with FSGS&#xD;
&#xD;
               2. UPCR &gt; 1.5 g/g&#xD;
&#xD;
               3. Screening eGFR ≥ 30 mL/min/1.73 m2&#xD;
&#xD;
               4. Subjects receiving systemic corticosteroids or calcineurin inhibitors must be on&#xD;
                  a stable dose for at least 12 weeks.&#xD;
&#xD;
               5. BMI ≤ 40 kg/m2&#xD;
&#xD;
          -  For patients enrolling in Alport syndrome Cohort:&#xD;
&#xD;
               1. Diagnosis of Alport syndrome by genetic testing&#xD;
&#xD;
               2. UPCR &gt; 0.5 g/g&#xD;
&#xD;
               3. Screening eGFR ≥ 30 mL/min/1.73 m2&#xD;
&#xD;
          -  For patients enrolling in DKD Cohort:&#xD;
&#xD;
               1. Diagnosis of type 2 diabetes mellitus&#xD;
&#xD;
               2. UACR ≥ 0.5 g/g&#xD;
&#xD;
               3. Screening eGFR ≥ 45 mL/min/1.73 m2&#xD;
&#xD;
               4. Receiving a stable dose of SGLT2 inhibitor for at least 12 weeks&#xD;
&#xD;
          -  Willing and able to provide informed consent and comply with all study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of another cause of chronic kidney disease or another primary&#xD;
             glomerulopathy.&#xD;
&#xD;
          -  History of kidney transplantation or other organ transplantation.&#xD;
&#xD;
          -  Except for FSGS patients, use of systemic immunosuppressant medications, such as&#xD;
             steroids, for more than 2 weeks in the past 3 months.&#xD;
&#xD;
          -  Blood pressure above 150 mmHg systolic or 95 mmHg diastolic as evaluated by the&#xD;
             Investigator.&#xD;
&#xD;
          -  History of heart failure or a previous hospital admission for fluid overload.&#xD;
&#xD;
          -  Clinically significant history of liver disease as assessed by the Investigator.&#xD;
&#xD;
          -  Hemoglobin below 9 g/dL as measured by the Investigator or blood transfusion for&#xD;
             anemia within the past 3 months.&#xD;
&#xD;
          -  Malignancy within the past 5 years. Exception to the criteria include nonmelanoma skin&#xD;
             cancer and curatively treated cervical carcinoma in situ.&#xD;
&#xD;
          -  For women, pregnant, breastfeeding, or intent to become pregnant during the study.&#xD;
&#xD;
          -  For men, intent to father a child or donate sperm during the study.&#xD;
&#xD;
          -  Recently received an investigational agent.&#xD;
&#xD;
          -  Clinically significant unstable or uncontrolled medical condition as assessed by the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Glicklich, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chinook Therapeutics</last_name>
    <phone>(206) 485-7051</phone>
    <email>clinicaltrials@chinooktx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nephrology Consultants, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesslyn Roesch</last_name>
      <phone>256-533-4626</phone>
      <email>jroesch@northalabamakidney.com</email>
    </contact>
    <investigator>
      <last_name>Carlo Castillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Research Institute</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jimmy Lee</last_name>
      <phone>626-318-9310</phone>
      <email>JimmyLee.CRI@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lakhi Sakhrani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidney Disease Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raffi Minasian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mohamed El-Shahawy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North America Research Institute</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syeda Naqvi</last_name>
      <phone>800-797-1695</phone>
      <phone_ext>118</phone_ext>
      <email>snaqvi@nariresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Yesenia Olivas</last_name>
      <phone>800-797-1695</phone>
      <phone_ext>118</phone_ext>
      <email>yguzman@nariresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aamir Jamal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Nephrology Research Institute</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Jodice</last_name>
      <phone>404-645-7150</phone>
      <phone_ext>3024</phone_ext>
      <email>ejodice@ganephrology.com</email>
    </contact>
    <investigator>
      <last_name>James Tumlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Srinivasa Iskapalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Wyle</last_name>
      <phone>617-636-2571</phone>
      <email>awyle@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Lesley Inker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelic Garay</last_name>
      <phone>702-271-4878</phone>
      <email>Angelic.Garay@DaVita.com</email>
    </contact>
    <investigator>
      <last_name>Mark Vishnepolsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountain Kidney and Hypertension Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Evans</last_name>
      <phone>828-258-8545</phone>
      <email>StephanieE@mtnkidney.com</email>
    </contact>
    <investigator>
      <last_name>Nam Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Rogers</last_name>
      <phone>336-245-6330</phone>
      <email>jrogers@brookviewhills.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas McLean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Disease Research Institute, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Akinwande Akinfolarin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Paso Kidney Specialists</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>German Hernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Kidney Disease Center Physicians Group, P.L.L.C</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Coppala</last_name>
      <phone>210-365-0051</phone>
      <email>Lauren.coppala@davita.com</email>
    </contact>
    <investigator>
      <last_name>Wesley Calhoun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Milwaukee Nephrologists, SC</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandra Jordan</last_name>
      <phone>262-364-4608</phone>
      <email>Chandra.jordan@davita.com</email>
    </contact>
    <investigator>
      <last_name>Lisa Rich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Research</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simon Roger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muh Geot Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dwarakanathan Ranganathan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melbourne Renal Research Group</name>
      <address>
        <city>Reservoir</city>
        <state>Victoria</state>
        <zip>3073</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Packham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri IRCCS</name>
      <address>
        <city>Pavia</city>
        <state>Lombardy</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ciro Esposito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sung-Gyun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Se Won Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seung Hyeok Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Publico da Marina</name>
      <address>
        <city>Burela</city>
        <state>Lugo</state>
        <zip>27880</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Secundino Cigarran Guldris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tamara Malek Marin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Nephritis, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrasentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

